When adult acne remains active despite treatment, the obvious question is whether a stronger therapy is needed.
But an Adult Acne Treatment can appear to fail for several reasons. The regimen may need more time. Irritation may reduce adherence. The phenotype may suggest a hormonal contribution. Or the treatment may no longer match the disease.
That makes “not working” less of a conclusion and more of a reason to reassess.
To understand how dermatologists approach these decisions, MDForLives surveyed specialists across six countries. The detailed findings are available in the MDForLives Adult Acne Management Insight Report.
Before changing the Treatment, ask if the current plan had a fair trial
In acne vulgaris, visible improvement is not always immediate. A regimen can therefore be judged before its effect can be assessed properly.
In the MDForLives survey, 43.5% of dermatologists identified slow visible improvement as the leading driver of treatment non-adherence or early dropout.
Before switching to therapy, ask: How long has it been used? How consistently? Did irritation lead to missed applications? Has inflammation improved even if clearance is incomplete?
An apparent acne treatment not working problem may reflect inadequate efficacy, insufficient time, inconsistent use, or poor tolerability.
The first reassessment is therefore: “Did this treatment have a fair opportunity to succeed?”
Slow improvement to an adherence problem
The question ‘how long does acne treatment take’ matters because expectations influence whether patients continue therapy long enough for it to be evaluated.
If improvement feels too slow, patients may stop treatment, use it intermittently, or switch regimens before reviewing.
Waiting is not always appropriate. Persistent inflammatory disease, scarring risk, or substantial psychosocial burden may justify a different strategy.
The task is to distinguish the expected gradual response from a genuine inadequate response. That makes expectation-setting part of treatment design: what improvement may look like, when it may become visible, and when reassessment is planned.
A realistic timeline can prevent an appropriate acne medication from being abandoned simply because improvement is not immediate.
Hormonal acne should change the questions before it changes the prescription
Adult acne is not one phenotype.
Lower-face or mandibular acne, persistent female acne, recurrence, and systemic features can raise a hormonal question. But not every adult with acne needs the same endocrine work-up.
In the survey, 51.1% of dermatologists said overt systemic signs such as hirsutism or irregular menses most commonly trigger hormonal or endocrine assessment. That matters when considering adult acne causes. The work-up should be driven by the clinical picture rather than adult age alone.
The broader lesson is that hormonal acne is a phenotype question before it becomes a medication question. If the pattern or associated history changes, the treatment logic may need to change too.
Some skin conditions can reflect broader biological or metabolic factors, making the clinical picture important beyond the visible symptoms. Explore how dermatologists are looking beyond the skin when evaluating these signals.
Tolerability can make an effective regimen
Treatment efficacy on paper does not guarantee effective treatment in daily use.
Topical irritation and barrier dryness were also prominent adherence problems. Persistent discomfort can reduce application or lead patients to stop treatment, particularly when post-inflammatory hyperpigmentation (PIH) is a concern.
Among surveyed dermatologists, 30.4% selected a gentler retinoid strategy as their primary adjustment for patients considered at high risk of PIH. The practical issue is whether the patient can use the regimen consistently without irritation undermining the plan.
When an Adult Acne Treatment underperforms, greater intensity is not automatically better. Sometimes the current plan first needs to become tolerable enough to use as intended.
Decide whether to repair, redirect, or escalate
When initial treatment did not provide adequate control, 37.0% of surveyed dermatologists said their most common next step was to optimize adherence and tolerability. A nearly equal 34.8% escalated or switched therapy.
That near split is the clinical story.
Some patients need stronger or different treatments. Others need the current plan to become usable before efficacy can be judged.
Before escalation, a short “failure check” may include duration, adherence, irritation, diagnosis, phenotype, hormonal or medical contributors, and PIH or scarring risk.
*When acne does not respond as expected, reassessing the clinical picture can be as important as changing treatment. Explore whether an online dermatologist assessment can provide enough information for a skin diagnosis.
If those factors are satisfactory and disease remains active, escalation becomes easier to justify. Otherwise, another drug may add burden without correcting why the first plan underperformed.
The key question is ‘whether the treatment failed or whether the pathway around the treatment failed.’
Escalation and maintenance are different conversations
For some adults, reassessment eventually leads to systemic treatment or isotretinoin. But escalation introduces a different decision from repairing an initial regimen.
In the survey, 46.7% of dermatologists identified patient concern about adverse effects as the leading barrier to prescribing oral isotretinoin in adult female acne.
That makes escalation partly a communication and acceptability question, not only a severity question. Risk, tolerability, expectations, pregnancy-prevention requirements where applicable, and willingness to proceed all affect whether an appropriate option can be used.
Improvement creates another question: what happens after control?
Adult acne should not be treated only as an induction problem. Maintenance needs its own plan because durable control depends on what the patient can realistically continue.
Closing perspective: before changing therapy, define what actually failed
When adult acne persists, changing treatment may be necessary, but it should not be the first assumption.
A practical reassessment asks whether the regimen had enough time, was tolerable enough to follow, still fits the phenotype, and whether hormonal clues, PIH, scarring, or relapse risk change the priority.
That creates a clearer treatment journey: confirm the response → check adherence and tolerability → reassess phenotype and contributors → decide whether to repair or escalate → plan for maintenance.
For dermatologists, the goal is not to prolong ineffective therapy. It is to understand why the current Adult Acne Treatment appears to have failed before escalating.
Frequently Asked Questions
Why does Adult Acne Treatment stop working?
Possible explanations include inadequate efficacy, inconsistent use, irritation, insufficient duration, hormonal or medical contributors, or a regimen that no longer matches the phenotype.
How long does acne treatment take to work?
Visible improvement can take several weeks and varies by treatment, severity, phenotype, and adherence. A planned review point helps distinguish gradual improvement from treatment failure.
When should hormonal acne be investigated?
Hormonal or endocrine assessment may be considered when history or examination suggests an underlying hormonal disorder, such as irregular menses, hirsutism, or other systemic features.
Can acne medication irritation affect treatment results?
Yes. Persistent dryness or irritation can reduce adherence. Dermatologists may adjust the regimen, formulation, frequency, or supportive skincare according to the clinical situation.
When is isotretinoin considered for adult acne?
Isotretinoin may be considered when acne is severe, carries significant scarring or psychosocial risk, or has not responded adequately to appropriate standard therapy. Treatment decisions require individualized assessment, counselling, and applicable safety measures.
